iBio, Inc. (IBIO) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2026, iBio reported revenue of $100,000, down 75.0% from $400,000 the year before. Net income was -$33.0M (a -33044.0% net margin), or -$0.32 per diluted share. Operating margin was -35141.0%. Operating activities generated -$23.2M of cash, leaving -$23.8M of free cash flow. At fiscal year end, iBio held $99.1M in total assets against $13.4M in total liabilities, including $56.4M of cash and equivalents.
Open the full interactive iBio financials → Quarterly statements, key ratios, valuation history and price charts.
iBio Key Stats
| Share Price | $0.78 |
|---|---|
| Market Cap | $81.2M |
| Revenue YoY Growth | -75.0% |
| 52-Week Range | $0.78 – $3.07 |
| Shares Outstanding | 104.1 million (basic, 2026 Q4) |
iBio Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Revenue | $2.4M | $2.4M | $0 | $225,000 | $400,000 | $100,000 |
| Cost of Goods Sold | $1.5M | $216,000 | — | — | — | — |
| Gross Profit | $909,000 | $2.2M | — | — | — | — |
| Operating Income | -$31.1M | -$49.7M | -$29.3M | -$16.6M | -$18.6M | -$35.1M |
| Pre-Tax Income | -$23.2M | -$50.3M | -$65.0M | -$24.9M | -$18.4M | -$33.0M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$23.2M | -$50.3M | -$65.0M | -$24.9M | -$18.4M | -$33.0M |
| Diluted EPS | -$60.00 | -$115.60 | -$106.20 | -$6.50 | -$1.75 | -$0.32 |
iBio Quarterly Results
| 2026 Q1 | 2026 Q2 | 2026 Q3 | 2026 Q4 | |
|---|---|---|---|---|
| Revenue | $100,000 | $0 | $0 | $0 |
| Net Income | -$5.7M | -$9.0M | -$7.7M | -$10.6M |
| Diluted EPS | -$0.11 | -$0.09 | -$0.06 | -$0.10 |
iBio Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $77.4M | $22.7M | $4.3M | $14.2M | $8.6M | $56.4M |
| Current Assets | $104.6M | $45.1M | $26.3M | $15.7M | $9.7M | $92.2M |
| Total Assets | $147.0M | $99.4M | $41.2M | $28.7M | $23.2M | $99.1M |
| Current Liabilities | $6.6M | $30.4M | $21.6M | $3.8M | $6.1M | $11.7M |
| Total Long-Term Debt | — | — | — | $984,000 | — | — |
| Total Liabilities | $38.4M | $35.9M | $25.8M | $7.4M | $8.3M | $13.4M |
| Shareholders' Equity | $108.6M | $63.5M | $15.4M | $21.3M | $14.9M | $85.7M |
iBio Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$30.1M | -$37.5M | -$30.4M | -$18.6M | -$15.3M | -$23.2M |
| Cash From Investing | -$26.5M | -$5.1M | $7.0M | $906,000 | $742,000 | -$32.0M |
| Cash From Financing | $78.8M | -$6.1M | $2.3M | $24.5M | $8.9M | $103.0M |
| Free Cash Flow | -$35.0M | -$44.8M | -$36.2M | -$18.8M | -$15.3M | -$23.8M |
Figures from iBio's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full iBio financials page for every line item.
iBio Company Profile
| Ticker | IBIO |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | New York, New York |
| Incorporated in | Delaware |
| Fiscal Year End | June 30 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001420720 |
Frequently Asked Questions
What was iBio's revenue in fiscal 2026?
iBio (IBIO) reported revenue of $100,000 for fiscal 2026.
What is iBio's annual revenue history?
iBio's annual revenue by fiscal year: 2021: $2.4M; 2022: $2.4M; 2023: $0; 2024: $225,000; 2025: $400,000; 2026: $100,000.
What was iBio's net income in fiscal 2026?
iBio reported net income of -$33.0M for fiscal 2026.
What was iBio's earnings per share (EPS) in fiscal 2026?
iBio's diluted EPS was -$0.32 for fiscal 2026 (adjusted for any later stock splits).
How much free cash flow did iBio generate in fiscal 2026?
iBio generated -$23.8M of free cash flow in fiscal 2026.
What was iBio's revenue last quarter?
In its most recent reported quarter (2026 Q4), iBio reported revenue of $0.
How many shares of iBio are outstanding?
iBio reported a weighted average of 104.1 million basic shares outstanding in 2026 Q4.
What is iBio's market cap?
Based on its latest closing price, iBio (IBIO) has a market capitalization of about $81.2M.
When does iBio's fiscal year end?
iBio's fiscal year end, as registered with the SEC, is June 30.
Where is iBio headquartered?
iBio lists its business address in New York, New York in its SEC filings.